Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Med Princ Pract ; 21(6): 538-42, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22571957

RESUMO

OBJECTIVE: This study was designed to investigate the relation between plasma von Willebrand factor (VWF) or endothelin-1 (ET-1) and post-carotid artery stenting (CAS) restenosis. MATERIALS AND METHODS: Plasma levels of VWF and ET-1 were measured in 61 patients (36 males, mean age 64.4 ± 6.8 years) before and after CAS. The mean follow-up time was 13.8 ± 1.7 months (range, 6-63). In-stent restenosis was defined as a >10% narrowing of the vascular lumen with or without ischemic symptoms following CAS. RESULTS: In-stent restenosis was identified in 14 (23%) patients, including 3 with >50% restenosis. In the restenosis group, mean VWF and ET-1 levels at 2 weeks, 1 and 6 months after CAS were higher than the baseline levels (p < 0.05 or p < 0.01). Mean levels of VWF and ET-1 in the restenosis group were higher than in the non-restenosis group within 6 months after CAS (p < 0.05 or p < 0.01). CONCLUSION: Persistent elevation in plasma VWF and ET-1 within the first 6 months of CAS was found in patients with in-stent restenosis.


Assuntos
Reestenose Coronária/diagnóstico , Vasos Coronários/patologia , Stents Farmacológicos , Endotelina-1/sangue , Acidente Vascular Cerebral , Fator de von Willebrand , Idoso , Análise de Variância , Biomarcadores Farmacológicos , Reestenose Coronária/tratamento farmacológico , Reestenose Coronária/patologia , Feminino , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Masculino , Pessoa de Meia-Idade , Inibidores da Agregação Plaquetária/uso terapêutico , Prognóstico , Estudos Prospectivos , Medição de Risco/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...